Cabotinib is used in the treatment of advanced renal cell carcinoma, and Anrotinib is mainly used in non-small cell lung cancer, and there are differences in indications and contraindications between them. Cabotinib is a kinase inhibitor and is used in patients with advanced renal cell carcinoma who have received previous anti-angiogenic therapy. Its frequent adverse reactions include fatigue, diarrhea, loss of appetite, nausea, palmar-plantar red sensory retardation syndrome, hypertension, weight loss, vomiting, and it is contraindicated in people who are allergic to this product. Anrotinib is clinically used for non-small cell lung cancer, clear cell sarcoma, adenoid soft tissue sarcoma, small cell lung cancer and other diseases, its common adverse reactions include fatigue, hypertension, gastrointestinal reactions, hand and foot skin reactions, liver function abnormalities. It is contraindicated for those who are allergic to the product, those with severe hepatic or renal insufficiency, pregnant and lactating women. Please select the appropriate medication according to the patient’s condition under the guidance of a physician, and do not use the medication blindly.